Table 4 Target proteins of drugs under clinical trials and with anti-SARS-CoV-2 activities
Drug category | Drug name | Direct host protein target |
|---|---|---|
Clinical trial | Metoprolol | ADRB2 |
Nebivolol | ADRB2 | |
Salicylic acid | CA9 | |
Pyridoxine | CBS | |
Cholecalciferol | CDC25A, VDR | |
Levocarnitine | CPT1A, SLC22A4 | |
Levofloxacin | CUL9, TOP2A | |
Losartan | CYP2C9 | |
Ifenprodil | EBP, SIGMAR1 | |
Propranolol | EHMT2, SIGMAR1, HTR2C, ADRB2 | |
Dapsone | G6PD | |
Salbutamol | GLP1R, ADRB2 | |
Atovaquone | GMNN | |
Acetaminophen | GSTP1 | |
Simvastatin | HMGCR | |
Vortioxetine | HTR3A, HTR2C, ADRB2 | |
L-Leucine | LARS, LARS2 | |
Nimesulide | LTF | |
Nadroparin | MYC, FOS | |
L-Citrulline | NOS2, OTC, ASS1 | |
Hydrocortisone | NR3C1 | |
Ribavirin | PBRM1, IMPDH2, IMPDH1 | |
Sildenafil | PDE2A | |
Ciclosporin | PPIF, CAMLG | |
Donepezil | SIGMAR1 | |
Fluvoxamine | SIGMAR1 | |
Epinephrine | SOD1, TNF, EHMT2, HIF1A, ADRB2 | |
Common | Venetoclax | BCL2, BCL2L1 |
Decitabine | GMNN | |
Amodiaquine | HIF1A | |
Mefenamic acid | HIF1A, CYP2C9, AKR1B1 | |
Toremifene | HNF4A, GMNN, ESR1 | |
Tetracycline | PRNP | |
Apremilast | TNF | |
Anti SARS-CoV-2 activity | Dienestrol | ADRB2, GMNN, ESR1 |
Amitriptyline | ADRB2, OPRM1, SIGMAR1, RET, NTRK1, DRD2, HTR2C | |
Hydrochlorothiazide | CA9 | |
Lurasidone | DRD2 | |
Adefovir dipivoxil | EHMT2 | |
Carvedilol | HIF1A, VCAM1, DRD2, APP, HTR2C, ADRB2 | |
Balsalazide | PPARG | |
Fenoprofen | PPARG | |
Repaglinide | PPARG | |
Calcipotriol | VDR |